$-0.96 EPS Expected for RXi Pharmaceuticals Corporation (RXII)

March 15, 2018 - By Michael Collier

 $ 0.96 EPS Expected for RXi Pharmaceuticals Corporation (RXII)

Analysts expect RXi Pharmaceuticals Corporation (NASDAQ:RXII) to report $-0.96 EPS on March, 29.They anticipate $5.04 EPS change or 84.00 % from last quarter’s $-6 EPS. After having $-1.10 EPS previously, RXi Pharmaceuticals Corporation’s analysts see -12.73 % EPS growth. The stock increased 42.19% or $1.35 during the last trading session, reaching $4.55. About 1.00 million shares traded or 306.49% up from the average. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 15, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $10.78 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

More notable recent RXi Pharmaceuticals Corporation (NASDAQ:RXII) news were published by: Prnewswire.com which released: “RXi Pharmaceuticals Announces Reverse Stock Split” on January 05, 2018, also Smallcapnetwork.com with their article: “RXi Pharmaceuticals Corp: Building a Foundation for a Breakout” published on November 18, 2016, Prnewswire.com published: “RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New …” on January 09, 2017. More interesting news about RXi Pharmaceuticals Corporation (NASDAQ:RXII) were released by: Prnewswire.com and their article: “RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire …” published on October 12, 2016 as well as Prnewswire.com‘s news article titled: “RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15 …” with publication date: August 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.